Raltegravir

Raltegravir
2
Clinical data
Trade namesIsentress
Other namesRAL
AHFS/Drugs.comMonograph
MedlinePlusa608004
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60% (FDA)
Protein binding83%
MetabolismLiver (UGT1A1)
Elimination half-life9 hours
Excretionfeces and urine
Identifiers
  • N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.124.631 Edit this at Wikidata
Chemical and physical data
FormulaC20H21FN6O5
Molar mass444.423 g·mol−1
3D model (JSmol)
  • Cc1nnc(o1)C(=O)NC(C)(C)C\3=N\C(C(=O)NCc2ccc(F)cc2)=C(\O)C(=O)N/3C
  • InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) checkY
  • Key:CZFFBEXEKNGXKS-UHFFFAOYSA-N checkY

Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS.[5] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.[6] It is taken by mouth.[5]

Common side effects include trouble sleeping, feeling tired, nausea, high blood sugar, and headaches.[6] Severe side effects may include allergic reactions including Stevens–Johnson syndrome, muscle breakdown, and liver problems.[6] It is unclear if use during pregnancy or breastfeeding is safe.[6] Raltegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.[6]

Raltegravir was approved for medical use in the United States in 2007.[6] It is on the World Health Organization's List of Essential Medicines.[7] Lamivudine/raltegravir, a combination with lamivudine, is also available.[6]

  1. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 1 April 2024.
  2. ^ "Isentress 400 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 July 2021.
  3. ^ "Isentress- raltegravir tablet, film coated Isentress- raltegravir tablet, chewable Isentress- raltegravir granule, for suspension". DailyMed. Retrieved 11 July 2021.
  4. ^ "Isentress EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 July 2021.
  5. ^ a b British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 429. ISBN 978-0-85711-156-2.
  6. ^ a b c d e f g "Raltegravir Potassium". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.